

Shmuel Shoham

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1089664/publications.pdf>

Version: 2024-02-01

99
papers

9,149
citations

76322

40
h-index

45310

90
g-index

106
all docs

106
docs citations

106
times ranked

13494
citing authors

#	ARTICLE	IF	CITATIONS
1	Lessons Learned from Coronavirus Disease 2019 (COVID-19) Therapies: Critical Perspectives From the Infectious Diseases Society of America (IDSA) COVID-19 Treatment Guideline Panel. <i>Clinical Infectious Diseases</i> , 2022, 74, 1691-1695.	5.8	16
2	Therapeutic Emergency Use Authorizations (EUAs) During Pandemics: Double-edged Swords. <i>Clinical Infectious Diseases</i> , 2022, 74, 1686-1690.	5.8	3
3	Pharmacokinetics of high-titer anti-SARS-CoV-2 human convalescent plasma in high-risk children. <i>JCI Insight</i> , 2022, 7, .	5.0	12
4	The silent and dangerous inequity around access to COVID-19 testing: A call to action. <i>EClinicalMedicine</i> , 2022, 43, 101230.	7.1	33
5	Adaptive immune responses in vaccinated patients with symptomatic SARS-CoV-2 Alpha infection. <i>JCI Insight</i> , 2022, 7, .	5.0	12
6	Antibody attributes that predict the neutralization and effector function of polyclonal responses to SARS-CoV-2. <i>BMC Immunology</i> , 2022, 23, 7.	2.2	6
7	Early Outpatient Treatment for Covid-19 with Convalescent Plasma. <i>New England Journal of Medicine</i> , 2022, 386, 1700-1711.	27.0	194
8	How do I implement an outpatient program for the administration of convalescent plasma for COVID-19?. <i>Transfusion</i> , 2022, , .	1.6	13
9	Outcomes of SOT Recipients With COVID-19 in Different Eras of COVID-19 Therapeutics. <i>Transplantation Direct</i> , 2022, 8, e1268.	1.6	14
10	Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern. <i>Blood Advances</i> , 2022, 6, 3678-3683.	5.2	42
11	Outcomes of transplant recipients treated with cidofovir for resistant or refractory cytomegalovirus infection. <i>Transplant Infectious Disease</i> , 2021, 23, e13521.	1.7	18
12	Comparative Performance of Five Commercially Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing Titers. <i>Journal of Clinical Microbiology</i> , 2021, 59, .	3.9	170
13	Quantifying infection risks in incompatible living donor kidney transplant recipients. <i>American Journal of Transplantation</i> , 2021, 21, 1564-1575.	4.7	9
14	ABO blood group and SARS-CoV-2 antibody response in a convalescent donor population. <i>Vox Sanguinis</i> , 2021, 116, 766-773.	1.5	22
15	Urgent needs of low-income and middle-income countries for COVID-19 vaccines and therapeutics. <i>Lancet</i> , The, 2021, 397, 562-564.	13.7	105
16	Correcting COVID-19 vaccine misinformation. <i>EClinicalMedicine</i> , 2021, 33, 100780.	7.1	63
17	EORTC/MSGERC Definitions of Invasive Fungal Diseases: Summary of Activities of the Intensive Care Unit Working Group. <i>Clinical Infectious Diseases</i> , 2021, 72, S121-S127.	5.8	109
18	Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	58

#	ARTICLE	IF	CITATIONS
19	Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma. MBio, 2021, 12, .	4.1	57
20	The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis. Mayo Clinic Proceedings, 2021, 96, 1262-1275.	3.0	129
21	Beyond the job: A need for global coordination of pharmacovigilance for COVID-19 vaccine deployment. EClinicalMedicine, 2021, 36, 100925.	7.1	11
22	Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence. Frontiers in Medicine, 2021, 8, 684151.	2.6	50
23	Urgent needs to accelerate the race for COVID-19 therapeutics. EClinicalMedicine, 2021, 36, 100911.	7.1	7
24	Transplant of SARS-CoV-2â€“infected Living Donor Liver: Case Report. Transplantation Direct, 2021, 7, e721.	1.6	16
25	Operation Warp Speed: implications for global vaccine security. The Lancet Global Health, 2021, 9, e1017-e1021.	6.3	72
26	Achieving global equity for COVID-19 vaccines: Stronger international partnerships and greater advocacy and solidarity are needed. PLoS Medicine, 2021, 18, e1003772.	8.4	7
27	Global public health security and justice for vaccines and therapeutics in the COVID-19 pandemic. EClinicalMedicine, 2021, 39, 101053.	7.1	45
28	Cytokine and Chemokine Levels in Coronavirus Disease 2019 Convalescent Plasma. Open Forum Infectious Diseases, 2021, 8, ofaa574.	0.9	41
29	Comparative performance of multiplex salivary and commercially available serologic assays to detect SARS-CoV-2 IgG and neutralization titers. Journal of Clinical Virology, 2021, 145, 104997.	3.1	28
30	Influenza-Associated Pulmonary Aspergillosis: Seek, and You Shall Find!. Critical Care Medicine, 2021, 49, e1265-e1266.	0.9	3
31	Long-term risk of hepatocellular carcinoma mortality in 23220 hospitalized patients treated with micafungin or other parenteral antifungals. Journal of Antimicrobial Chemotherapy, 2020, 75, 221-228.	3.0	6
32	A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Lower Respiratory Tract. Clinical Infectious Diseases, 2020, 71, 2787-2795.	5.8	44
33	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clinical Infectious Diseases, 2020, 71, 1367-1376.	5.8	1,429
34	The Assessment of Convalescent Plasma Efficacy against COVID-19. Med, 2020, 1, 66-77.	4.4	17
35	Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study. Lancet HIV,the, 2020, 7, e602-e610.	4.7	11
36	SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors. Journal of Infectious Diseases, 2020, 222, 1974-1984.	4.0	96

#	ARTICLE	IF	CITATIONS
37	Management of Indwelling Tunneled Pleural Catheters. <i>Chest</i> , 2020, 158, 2221-2228.	0.8	25
38	Clinical characteristics and outcomes of invasive <i>Lomentospora prolificans</i> infections: Analysis of patients in the FungiScope registry. <i>Mycoses</i> , 2020, 63, 437-442.	4.0	41
39	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With Coronavirus Disease 2019 (COVID-19). <i>Clinical Infectious Diseases</i> , 2020, , .	5.8	708
40	Deployment of convalescent plasma for the prevention and treatment of COVID-19. <i>Journal of Clinical Investigation</i> , 2020, 130, 2757-2765.	8.2	649
41	Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. <i>Journal of Clinical Investigation</i> , 2020, 130, 6141-6150.	8.2	375
42	MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3056-3062.	3.0	54
43	Angioinvasive, cutaneous infection due to <i>Colletotrichum siamense</i> in a stem cell transplant recipient: Report and review of prior cases. <i>Transplant Infectious Disease</i> , 2019, 21, e13153.	1.7	5
44	Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 941-950.	10.7	83
45	Total Penis, Scrotum, and Lower Abdominal Wall Transplantation. <i>New England Journal of Medicine</i> , 2019, 381, 1876-1878.	27.0	31
46	Emerging fungal infections in solid organ transplant recipients: Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clinical Transplantation</i> , 2019, 33, e13525.	1.6	49
47	Outcomes of patients with invasive fusariosis who undergo further immunosuppressive treatments, is there a role for secondary prophylaxis?. <i>Mycoses</i> , 2019, 62, 413-417.	4.0	18
48	2686. strong Bloodstream Infection Survey in High-Risk Oncology Patients (BISHOP) with Fever and Neutropenia (FN): Viridans Group Streptococcus Emerges as an Important Pathogen. <i>Open Forum Infectious Diseases</i> , 2019, 6, S943-S944.	0.9	0
49	Updates on the Treatment of Non-Aspergillus Hyaline Mold Infections. <i>Current Fungal Infection Reports</i> , 2019, 13, 308-319.	2.6	1
50	Single Academic Center Experience of Unrestricted β -d-Glucan Implementation. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy195.	0.9	8
51	Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study. <i>Lancet Respiratory Medicine</i> , 2017, 5, 500-511.	10.7	85
52	Graded isavuconazole introduction in a patient with voriconazole allergy. <i>Transplant Infectious Disease</i> , 2017, 19, e12772.	1.7	8
53	A Mycoses Study Group International Prospective Study of Phaeohyphomycosis: An Analysis of 99 Proven/Probable Cases. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx200.	0.9	43
54	Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 882-913.	4.9	293

#	ARTICLE	IF	CITATIONS
55	Short-term risk of liver and renal injury in hospitalized patients using micafungin: a multicentre cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2938-2944.	3.0	15
56	Antimicrobial Access in the 21st Century: Delays and Critical Shortages. <i>Annals of Internal Medicine</i> , 2016, 165, 53.	3.9	3
57	Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection. <i>Transplantation</i> , 2016, 100, e74-e80.	1.0	120
58	Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by <i>Aspergillus</i> and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. <i>Lancet, The</i> , 2016, 387, 760-769.	13.7	695
59	Host/Pathogen Interactions in Fungal Keratitis. <i>Current Fungal Infection Reports</i> , 2015, 9, 52-56.	2.6	4
60	<i>Cryptococcus neoformans</i> Prosthetic Joint Infection: Case Report and Review of the Literature. <i>Mycopathologia</i> , 2015, 179, 275-278.	3.1	15
61	High Proportion of Indeterminate QuajaERON-TB Gold In-Tube Results in an Inpatient Population Is Related to Host Factors and Preanalytical Steps. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu088.	0.9	18
62	Very Low Levels of 25-Hydroxyvitamin D Are Not Associated With Immunologic Changes or Clinical Outcome in South African Patients With HIV-Associated Cryptococcal Meningitis. <i>Clinical Infectious Diseases</i> , 2014, 59, 493-500.	5.8	10
63	MSG-01: A Randomized, Double-Blind, Placebo-Controlled Trial of Caspofungin Prophylaxis Followed by Preemptive Therapy for Invasive Candidiasis in High-Risk Adults in the Critical Care Setting. <i>Clinical Infectious Diseases</i> , 2014, 58, 1219-1226.	5.8	142
64	The Natural History of Influenza Infection in the Severely Immunocompromised vs Nonimmunocompromised Hosts. <i>Clinical Infectious Diseases</i> , 2014, 58, 214-224.	5.8	197
65	Real-World Experience with Echinocandin MICs against <i>Candida</i> Species in a Multicenter Study of Hospitals That Routinely Perform Susceptibility Testing of Bloodstream Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1897-1906.	3.2	59
66	Emerging Fungal Infections in Solid Organ Transplant Recipients. <i>Infectious Disease Clinics of North America</i> , 2013, 27, 305-316.	5.1	38
67	Impact of Multidrug-Resistant Organisms on Patients Considered for Lung Transplantation. <i>Infectious Disease Clinics of North America</i> , 2013, 27, 343-358.	5.1	30
68	Treatment of Iatrogenic Fungal Infections: A Black Mold Defines a New Gray Zone in Medicine. <i>Annals of Internal Medicine</i> , 2013, 158, 208.	3.9	3
69	Invasive fungal infections in solid organ transplant recipients. <i>Future Microbiology</i> , 2012, 7, 639-655.	2.0	142
70	Diagnostic and therapeutic challenges in a liver transplant recipient with central nervous system invasive aspergillosis. <i>Diagnostic Microbiology and Infectious Disease</i> , 2012, 73, 374-375.	1.8	4
71	Early serum (1 α) ³ â€”glucan levels in patients with burn injury. <i>Mycoses</i> , 2012, 55, 224-227.	4.0	10
72	Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. <i>Mycoses</i> , 2011, 54, 46-51.	4.0	98

#	ARTICLE	IF	CITATIONS
73	Invasive Candidiasis in Patients with Implants. <i>Current Fungal Infection Reports</i> , 2011, 5, 12-17.	2.6	1
74	The Role of Genetics in Host Responses to Mucosal and Invasive Candidiasis. <i>Current Fungal Infection Reports</i> , 2011, 5, 262-268.	2.6	2
75	The Growing Role of Clinical and Genomic Databases in the Development of Antifungal Strategies. <i>Current Fungal Infection Reports</i> , 2011, 5, 190-192.	2.6	0
76	Invasive Fungal Infections in the ICU. <i>Journal of Intensive Care Medicine</i> , 2010, 25, 78-92.	2.8	46
77	Serial Spinal Taps Prevent Complications from Elevated CSF Pressure in Cryptococcal Meningitis. <i>Current Fungal Infection Reports</i> , 2010, 4, 200-202.	2.6	0
78	Primary treatment of zygomycosis with liposomal amphotericin B: analysis of 28 cases. <i>Medical Mycology</i> , 2010, 48, 511-517.	0.7	68
79	Evaluation of <i>mupA</i> Evigene in Comparison to Disk Diffusion for Detection of High-Level Mupirocin Resistance in Clinical Isolates of <i>Staphylococcus aureus</i> . <i>Journal of Clinical Microbiology</i> , 2010, 48, 2953-2954.	3.9	1
80	Effects of Immunomodulatory and Organism-Associated Molecules on the Permeability of an <i>In Vitro</i> Blood-Brain Barrier Model to Amphotericin B and Fluconazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1305-1310.	3.2	15
81	Epidemiological and Microbiological Features of Ventricular Assist Device Associated Infections. <i>Journal of Cardiac Failure</i> , 2010, 16, S115.	1.7	0
82	Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. <i>Lancet Infectious Diseases</i> , The, 2010, 10, 521-526.	9.1	329
83	Acute Bacterial Suppurative Thyroiditis: A Clinical Review and Expert Opinion. <i>Thyroid</i> , 2010, 20, 247-255.	4.5	173
84	Association Between Blood Glucose Levels and Development of Candidemia in Hospitalized Patients. <i>Endocrine Practice</i> , 2009, 15, 111-115.	2.1	8
85	Cardiac assist device infections. <i>Current Infectious Disease Reports</i> , 2009, 11, 268-273.	3.0	16
86	Augmentation of innate host defenses against opportunistic fungal pathogens. <i>Current Fungal Infection Reports</i> , 2009, 3, 186-191.	2.6	1
87	Pneumocystis pneumonia in children. <i>Paediatric Respiratory Reviews</i> , 2009, 10, 192-198.	1.8	54
88	Pulmonary Zygomycosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2008, 29, 111-120.	2.1	26
89	Impact upon clinical outcomes of translation of PNA FISH-generated laboratory data from the clinical microbiology bench to bedside in real time. <i>Therapeutics and Clinical Risk Management</i> , 2008, Volume 4, 637-640.	2.0	97
90	The pharmacology and clinical use of caspofungin. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2007, 3, 263-274.	3.3	26

#	ARTICLE	IF	CITATIONS
91	Candidemia in Patients with Ventricular Assist Devices. <i>Clinical Infectious Diseases</i> , 2007, 44, e9-e12.	5.8	29
92	Clinical Research in the Lay Press: Irresponsible Journalism Raises a Huge Dose of Doubt. <i>Clinical Infectious Diseases</i> , 2006, 43, 1031-1039.	5.8	3
93	The immune response to fungal infections. <i>British Journal of Haematology</i> , 2005, 129, 569-582.	2.5	327
94	Amikacin and colistin for treatment of <i>Acinetobacter baumannii</i> meningitis. <i>Journal of Infection</i> , 2005, 51, e249-e251.	3.3	32
95	<i>Cryptococcus neoformans</i> Meningitis at 2 Hospitals in Washington, D.C.: Adherence of Health Care Providers to Published Practice Guidelines for the Management of Cryptococcal Disease. <i>Clinical Infectious Diseases</i> , 2005, 40, 477-479.	5.8	66
96	Involvement of CD14, Toll-Like Receptors 2 and 4, and MyD88 in the Host Response to the Fungal Pathogen <i>Cryptococcus neoformans</i> In Vivo. <i>Infection and Immunity</i> , 2004, 72, 5373-5382.	2.2	173
97	Detection of Galactomannan Antigenemia in Patients Receiving Piperacillin-Tazobactam and Correlations between In Vitro, In Vivo, and Clinical Properties of the Drug-Antigen Interaction. <i>Journal of Clinical Microbiology</i> , 2004, 42, 4744-4748.	3.9	138
98	Neurosyphilis Masquerading as Herpes Encephalitis. <i>Infectious Diseases in Clinical Practice</i> , 2004, 12, 30-31.	0.3	1
99	Toll-Like Receptor 4 Mediates Intracellular Signaling Without TNF- α Release in Response to <i>Cryptococcus neoformans</i> Polysaccharide Capsule. <i>Journal of Immunology</i> , 2001, 166, 4620-4626.	0.8	301